Discover
IMUX
Immunic, Inc.
14.81
2 x 10.96
2 x 19.09
bid
ask
-
0.56
3.64%
2 @ 04:00 PM
14.29 -0.52 (3.52%)
| Ytd | 177.34% | |
| 1y | 114.64% |
14.77
day range
15.42
5.06
52 week range
15.84
| Open | 15.21 | Prev Close | 15.37 | Low | 14.77 | High | 15.42 | Mkt Cap | 201.73M |
| Vol | 100.71K | Avg Vol | 270.54K | EPS | -4.77 | P/E | N/A | Forward P/E | -1.67 |
| Beta | 1.88 | Short Ratio | 4.69 | Inst. Own | 64.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 12.63 | 200-d Avg | 9.50 | 1yr Est | 12.79 |
| Income Statement | |||
| Operating Expenses | 33.24M | ||
| Research and Development Expense | 25.63M | ||
| Selling, General and Administrative Expense | 7.61M | ||
| Operating Income | -33.23M | ||
| Net Income | -32.59M | ||
| Net Income Common Stock | -32.59M | ||
| Net Income Common Stock (USD) | -32.59M | ||
| Consolidated Income | -32.59M | ||
| Earnings per Basic Share | -1.08 | ||
| Earnings per Basic Share (USD) | -1.08 | ||
| Earnings per Diluted Share | -1.08 | ||
| Earning Before Interest & Taxes (EBIT) | -32.59M | ||
| Earning Before Interest & Taxes (USD) | -32.59M | ||
| Weighted Average Shares | 30.14M | ||
| Weighted Average Shares Diluted | 30.14M | ||
| Balance Sheet | |||
| Cash and Equivalents | 186.63M | ||
| Cash and Equivalents (USD) | 186.63M | ||
| Current Assets | 188.76M | ||
| Property, Plant & Equipment Net | 983.00K | ||
| Total Assets | 189.74M | ||
| Total Debt | 146.00K | ||
| Current Liabilities | 38.36M | ||
| Debt Non-Current | 146.00K | ||
| Total Liabilities | 38.51M | ||
| Accumulated Retained Earnings (Deficit) | -641.16M | ||
| Accumulated Other Comprehensive Income | 3.06M | ||
| Shareholders Equity | 151.23M | ||
| Shareholders Equity (USD) | 151.23M | ||
| Assets Non-Current | 983.00K | ||
| Total Debt (USD) | 146.00K | ||
| Liabilities Non-Current | 146.00K | ||
| Trade and Non-Trade Payables | 11.01M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 184.00K | ||
| Net Cash Flow from Financing | 188.64M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 171.15M | ||
| Capital Expenditure | -2.00K | ||
| Issuance (Purchase) of Equity Shares | 188.64M | ||
| Net Cash Flow from Investing | -2.00K | ||
| Net Cash Flow from Operations | -17.30M | ||
| Effect of Exchange Rate Changes on Cash | -193.00K | ||
| Share Based Compensation | 4.47M | ||